Skip to main content
Log in

Comparison of cardio-focal and chest reconstruction of technetium-99m pyrophosphate scintigraphy for diagnosis of transthyretin cardiac amyloidosis: a quality assurance study

  • BRIEF REPORT
  • Published:
Journal of Nuclear Cardiology Aims and scope

Abstract

Background

SPECT improves diagnostic specificity of Technetium-99m pyrophosphate (PYP) scintigraphy. Diagnostic performance of PYP data, reconstructed as either chest or cardio-focal SPECT is not known.

Methods

In this quality assurance study, blinded evaluation of PYP SPECT/CT data from 102 Caucasian patients (mean age 76 ± 11 years, 67% men) was performed by two readers. Reader 1 reviewed planar and PYP chest SPECT, while reader 2 reviewed planar and cardio-focal PYP SPECT. Demographic, clinical, and other testing data were obtained from the electronic medical records.

Results

A total of 41 patients (40%) were considered positive based on myocardial uptake on chest PYP SPECT. Of these, 98% of the patients had a Perugini score ≥ 2 on planar imaging. There was good agreement between the two readers for visual score ≥ 2 (k = .88, P < .001) and excellent agreement for myocardial uptake on tomographic imaging (98%, P < .001). Only one study was categorized as false negative by cardio-focal SPECT reconstruction. Non-diffuse myocardial uptake was identified in 22% of those with a positive PYP SPECT.

Conclusion

When read by experienced readers, chest and cardio-focal reconstruction of PYP SPECT have comparable diagnostic performance. A substantial proportion of patients with a positive PYP SPECT have a non-diffuse distribution of PYP. Given the possibility of misclassification of non-diffuse myocardial uptake on cardio-focal reconstruction alone, chest reconstruction of PYP scintigraphy should be strongly considered.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Abbreviations

CA:

Cardiac amyloidosis

PYP:

Technetium-99m pyrophosphate

ATTR:

Transthyretin amyloidosis

FOV:

Field of view

CZT:

Cadmium-zinc-telluride

LV:

Left ventricular

H/CL:

Heart to contralateral lung

CKD:

Chronic kidney disease

LVEF:

Left ventricular ejection fraction

IVSd:

Interventricular septum thickness in diastole

References

  1. Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol 2019;26:2065‐123.

    Article  PubMed  Google Scholar 

  2. Poterucha TJ, Elias P, Bokhari S, Einstein AJ, DeLuca A, Kinkhabwala M, et al. Diagnosing transthyretin cardiac amyloidosis by technetium Tc 99m pyrophosphate. JACC 2021;14:1221‐31.

    PubMed  Google Scholar 

  3. Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016;133:2404‐12.

    Article  CAS  PubMed  Google Scholar 

  4. Sperry BW, Burgett E, Bybee KA, McGhie AI, O’Keefe JH, Saeed IM, et al. Technetium pyrophosphate nuclear scintigraphy for cardiac amyloidosis: Imaging at 1 vs 3 hours and planar vs SPECT/CT. J Nucl Cardiol 2020;27:1802‐7.

    Article  PubMed  Google Scholar 

  5. Asif T, Gomez J, Singh V, Doukky R, Nedeltcheva A, Malhotra S. Comparison of planar with tomographic pyrophosphate scintigraphy for transthyretin cardiac amyloidosis: Perils and pitfalls. J Nucl Cardiol 2021;28:104‐11.

    Article  PubMed  Google Scholar 

  6. Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol 2021;28:1769‐74.

    Article  PubMed  Google Scholar 

  7. Urbain J-L, Richardson J, Ross A, Khider M, Akincioglu C. CANM cardiac amyloid PYP imaging guidelines. Can Assoc Nucl Med.

  8. Asif T, Gupta A, Murthi M, Soman P, Singh V, Malhotra S. Echocardiographic indices of left ventricular function and filling pressure are not related to blood pool activity on pyrophosphate scintigraphy. J Nucl Cardiol 2022. https://doi.org/10.1007/s12350-022-02989-4.

    Article  PubMed  Google Scholar 

  9. Asif T, Vij A, Radzik B, Stern H, Simples P, Ghadiali Q, et al. Multimodality imaging for diagnosis of subclinical hereditary transthyretin cardiac amyloidosis. J Nucl Cardiol 2021. https://doi.org/10.1007/s12350-021-02865-7.

    Article  PubMed  Google Scholar 

  10. Tamarappoo B, Otaki Y, Manabe O, Hyun M, Cantu S, Arnson Y, et al. Simultaneous Tc-99m PYP/Tl-201 dual-isotope SPECT myocardial imaging in patients with suspected cardiac amyloidosis. J Nucl Cardiol 2020;27:28‐37.

    Article  PubMed  Google Scholar 

  11. Tilkemeier PL, Bourque J, Doukky R, Sanghani R, Weinberg RL. ASNC imaging guidelines for nuclear cardiology procedures: Standardized reporting of nuclear cardiology procedures. J Nucl Cardiol 2017;24:2064‐128.

    Article  PubMed  Google Scholar 

Download references

Disclosure

Cigdem Akincioglu received research support from Pfizer; Mukunthan Murthy had none; Jonathan Romsa had none to disclose; James Warrington had— none to disclose; Saurabh Malhotra received research support from ASNC/Pfizer Inc., is one of the members in Speakers Bureau for Pfizer Inc. and Alnylam, and is an advisory board member for Pfizer, Alnylam, and BridgeBio.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Cigdem Akincioglu MD.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The authors of this article have provided a PowerPoint file, available for download at SpringerLink, which summarises the contents of the paper and is free for re-use at meetings and presentations. Search for the article DOI on SpringerLink.com.

The authors have also provided an audio summary of the article, which is available to download as ESM, or to listen to via the JNC/ASNC Podcast.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (PPTX 733 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Akincioglu, C., Murthi, M., Romsa, J. et al. Comparison of cardio-focal and chest reconstruction of technetium-99m pyrophosphate scintigraphy for diagnosis of transthyretin cardiac amyloidosis: a quality assurance study. J. Nucl. Cardiol. 30, 2607–2614 (2023). https://doi.org/10.1007/s12350-023-03256-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12350-023-03256-w

Keywords

Navigation